For patients with polycythemia vera, managing excess red blood cell production can often involve frequent phlebotomy. Mimrylo (rusfertide) takes a different approach by working with the body’s natural iron-regulation system.
By mimicking hepcidin, a hormone that controls iron availability, Mimrylo helps limit the iron needed to produce new red blood cells. This offers a new way to manage erythrocytosis in adults with polycythemia vera.
As the first approved therapy of its kind for this condition, Mimrylo introduces a new treatment approach in hematology. Its market uptake and availability will be important to watch as it enters clinical practice.
